Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

66 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia.
Zaja F, Baccarani M, Mazza P, Bocchia M, Gugliotta L, Zaccaria A, Vianelli N, Defina M, Tieghi A, Amadori S, Campagna S, Ferrara F, Angelucci E, Usala E, Cantoni S, Visani G, Fornaro A, Rizzi R, De Stefano V, Casulli F, Battista ML, Isola M, Soldano F, Gamba E, Fanin R. Zaja F, et al. Among authors: defina m. Blood. 2010 Apr 8;115(14):2755-62. doi: 10.1182/blood-2009-07-229815. Epub 2010 Feb 3. Blood. 2010. PMID: 20130241 Free article. Clinical Trial.
Pilot study of gemtuzumab ozogamicin (GO), fludarabine, cytarabine and idarubicin combined regimen (GO-FLAI) as first-line induction therapy plus GO alone as consolidation therapy for elderly acute myeloid leukemia patients.
Pirrotta MT, Bocchia M, Bucalossi A, Defina M, Forconi F, Gozzetti A, Lauria F. Pirrotta MT, et al. Among authors: defina m. Acta Haematol. 2007;118(1):7-9. doi: 10.1159/000100992. Epub 2007 Mar 26. Acta Haematol. 2007. PMID: 17389781 No abstract available.
Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura.
Zaja F, Battista ML, Pirrotta MT, Palmieri S, Montagna M, Vianelli N, Marin L, Cavallin M, Bocchia M, Defina M, Ippoliti M, Ferrara F, Patriarca F, Avanzini MA, Regazzi M, Baccarani M, Isola M, Soldano F, Fanin R. Zaja F, et al. Among authors: defina m. Haematologica. 2008 Jun;93(6):930-3. doi: 10.3324/haematol.12206. Epub 2008 Apr 9. Haematologica. 2008. PMID: 18403395 Free article.
Cutaneous myeloma and bortezomib.
Gozzetti A, Defina M, Bocchia M. Gozzetti A, et al. Among authors: defina m. Ann Hematol. 2009 Oct;88(10):1045. doi: 10.1007/s00277-009-0786-7. Epub 2009 Jul 14. Ann Hematol. 2009. PMID: 19597817 Free article. No abstract available.
Hyperlipidemic myeloma.
Gozzetti A, Defina M, Bocchia M, Lauria F. Gozzetti A, et al. Among authors: defina m. Ann Hematol. 2010 Sep;89(9):939-40. doi: 10.1007/s00277-010-0905-5. Epub 2010 Feb 2. Ann Hematol. 2010. PMID: 20127090 No abstract available.
Low-dose rituximab in adult patients with primary immune thrombocytopenia.
Zaja F, Vianelli N, Volpetti S, Battista ML, Defina M, Palmieri S, Bocchia M, Medeot M, De Luca S, Ferrara F, Isola M, Baccarani M, Fanin R. Zaja F, et al. Among authors: defina m. Eur J Haematol. 2010 Oct;85(4):329-34. doi: 10.1111/j.1600-0609.2010.01486.x. Epub 2010 Jul 28. Eur J Haematol. 2010. PMID: 20546023 Clinical Trial.
Lenalidomide efficacy in bortezomib-resistant myeloma.
Gozzetti A, Crupi R, Defina M, Bocchia M. Gozzetti A, et al. Among authors: defina m. Nat Rev Clin Oncol. 2010 Sep;7(9). doi: 10.1038/nrclinonc.2010.31-c2. Nat Rev Clin Oncol. 2010. PMID: 20824907 No abstract available.
66 results